Cubist Systematic Strategies LLC Has $69,000 Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Cubist Systematic Strategies LLC lessened its position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 30.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,371 shares of the company’s stock after selling 12,278 shares during the period. Cubist Systematic Strategies LLC owned 0.07% of Werewolf Therapeutics worth $69,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Point72 DIFC Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $34,000. Rhumbline Advisers acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $79,000. American Century Companies Inc. increased its holdings in Werewolf Therapeutics by 50.7% in the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock worth $92,000 after purchasing an additional 12,656 shares in the last quarter. Murchinson Ltd. acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $152,000. Finally, Bank of New York Mellon Corp acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $165,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HOWL. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Tuesday, July 2nd. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Werewolf Therapeutics in a research note on Wednesday, June 26th.

Werewolf Therapeutics Trading Up 2.5 %

Shares of HOWL stock opened at $2.06 on Thursday. The stock has a market cap of $89.52 million, a price-to-earnings ratio of -1.89 and a beta of 0.45. The stock has a 50-day moving average of $2.10 and a 200-day moving average of $3.38. The company has a current ratio of 12.13, a quick ratio of 12.13 and a debt-to-equity ratio of 0.24. Werewolf Therapeutics, Inc. has a 1-year low of $1.57 and a 1-year high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Werewolf Therapeutics had a negative return on equity of 48.25% and a negative net margin of 578.80%. The business had revenue of $1.14 million for the quarter, compared to analyst estimates of $2.00 million. On average, equities research analysts forecast that Werewolf Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.